Safety alerts, recalls, shortages, labeling changes, and medication warnings from trusted authorities.
A nationwide hospital-level recall is underway for one lot of magnesium sulfate after FDA said a pouch was found to contain tranexamic acid instead. The issue matters because both drugs are used in urgent care, but FDA said it had not received adverse-event reports at the time of the announcement.
The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from a key bulk-substance list used by outsourcing compounding facilities. The move follows the agency’s view that national GLP-1 supply has stabilized and that the shortage-driven flexibility is no longer needed.
The FDA has issued two separate safety notices that may affect hospitals and patients: a nationwide recall of certain B. Braun Lactated Ringer’s Injection 1L lots because of particulate matter, and a shortage notice for neurosurgical patties, sponges and strips. The actions are different, but both can affect procedure planning, supply checks and patient safety.
A recall is not the same as a shortage. One means a product may be unsafe or defective; the other means supply is limited or disrupted. The latest FDA updates include a May 6 device shortage addition, an April 28 recall of lactated Ringer’s injection, and new reminders about how GLP-1 supply changes affect compounded versions.
Two recent FDA notices involving injectable medicines are a reminder that hospital IV recalls are usually specific, lot-based safety actions — not a signal that every product in a category is unsafe. The latest alerts involve a magnesium sulfate mix-up and lactated Ringer’s solution with particulate matter.
The FDA says a shortage of neurosurgical patties, sponges, and strips may continue through the end of 2026. The agency is asking hospitals and surgical teams to conserve supplies, prioritize essential cases, and plan for alternatives when appropriate.
The FDA is proposing new limits on compounded versions of semaglutide, tirzepatide, and liraglutide as national supply conditions improve. The change would not take effect immediately, and access could still vary by pharmacy, state rules, and insurance coverage.
The CDC says the Bicillin L-A shortage is still ongoing, and that matters because this is the preferred penicillin treatment for syphilis in pregnancy. Officials say limited supply should be preserved for pregnant patients whenever possible, while some areas may also use temporarily imported Lentocilin to help fill gaps.
A late-April FDA recall of B. Braun Lactated Ringer’s Injection is mainly a hospital supply issue, but it can matter for patients who may have received the affected IV fluid. The key questions are whether a facility used one of the recalled lots, whether any symptoms followed, and how to report concerns.
The FDA says B. Braun has recalled two lots of Lactated Ringer’s Injection after particulate matter was found in the solution. The recall mainly affects hospitals, clinics, and other facilities that stocked the affected lots, but patients who recently received this IV fluid may want to check with the treating facility if they have concerns.
The FDA says certain Omnipod 5 pods are part of a Class I recall because a manufacturing defect may let insulin leak inside the pod. The notice says affected users should stop using impacted pods, check lot numbers, and switch to unaffected pods or contact Insulet for replacements.
The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list, a move that could affect some compounded GLP-1 products. Patients using compounded versions should not make changes on their own; they should check with the prescriber or pharmacist about supply, cost, and next steps.
The FDA is moving to narrow when compounders can make semaglutide, tirzepatide, and liraglutide as national shortages improve. For people using compounded GLP-1 medicines, the practical next step is to check exactly what product they have and confirm any changes with a clinician or pharmacist.
The FDA has proposed withdrawing Tavneos, but it has not ordered an immediate recall. For patients with ANCA-associated vasculitis, the key step right now is to contact the prescribing specialist before stopping, switching, or delaying treatment.
A nationwide recall of one Children’s Advil bottle is a reminder to check the lot number before giving any medicine to a child. The FDA said the risk was remote, but families should stop using a suspected bottle and confirm the package details before assuming it is safe.
The Bicillin L-A shortage is still ongoing, and CDC says limited supplies should be preserved for pregnant patients whenever possible. Here’s what that means for syphilis treatment access, temporary alternatives, and what to do if a pharmacy cannot fill a prescription.
The FDA’s March 13 update added two device categories, removed one, and extended several shortage timelines. Most patients will not be affected, but hospitals, clinics, and surgeons may need to adjust planning when a device on the list is part of a scheduled procedure.
A nationwide recall of children’s ibuprofen bottles may sound alarming, but federal regulators say the chance of serious harm is remote. The practical next step is simple: check the bottle details against the FDA recall notice before using it again.
FDA says semaglutide supply is stabilizing, which changes when compounded GLP-1 products may be allowed. The agency is also warning about dosing mistakes, quality problems, and misleading marketing tied to compounded versions of semaglutide and tirzepatide.
A federal import plan may ease some Bicillin L-A shortages, but access can still vary. For pregnancy, penicillin remains the only recommended syphilis treatment.
The FDA now requires new warnings on carbidopa/levodopa labels about vitamin B6 deficiency and possible seizures, with advice on testing and monitoring.
FDA approved the first generic Flovent HFA, but access may still depend on strength, pharmacy supply, insurance coverage, and safe switching.
End of content
End of content